cDNA PATENT POSITION NEEDS "FOCUS" FROM PhRMA, CLEVELAND CLINIC's HEALY ADVISES; SMITHKLINE CATALOG HOLDS 85% OF "KNOWN HUMAN GENES," SB REPORTS
Executive Summary
The "quietly exploding" arena of cDNA research requires PhRMA to formulate a party-line on the issue of recombinant DNA patenting, Bernadine Healy, MD, advised the Pharmaceutical Research & Manufacturers of America at its annual meeting March 24 in Washington, D.C.